Urine Markers May Aid Psych Diagnosis - Report - MDSpire
Advertisement
Urine Markers May Aid Psych Diagnosis
Genetically predicted urinary metabolite levels were associated with schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and anorexia nervosa in a Mendelian randomization analysis.
Clinical Report: Urine Markers May Aid Psych Diagnosis
Overview
A two-sample Mendelian randomization study identified genetically predicted associations between urinary metabolites and psychiatric disorders, suggesting potential biomarkers for differential diagnosis. Notably, inverse associations were found between genetically predicted urinary tyrosine and schizophrenia, and urinary creatine and bipolar disorder.
Background
The identification of biomarkers for psychiatric disorders is critical for improving diagnostic accuracy and treatment outcomes. Current diagnostic practices primarily rely on clinical assessments and observational studies, which can lead to misdiagnosis. This study explores the genetic links between urinary metabolites and psychiatric conditions using GWAS data, potentially paving the way for future diagnostic tools.
Data Highlights
Metabolite
Associated Disorder
Tyrosine
Schizophrenia
Creatine
Bipolar Disorder
N,N-dimethylglycine
ADHD
Pyridoxal
Anorexia Nervosa
Ferulic Acid 4-Sulfate
Anorexia Nervosa
Beta-citrylglutamate
Schizophrenia
Methylsuccinate
Schizophrenia
Ethylmalonate
Schizophrenia
2-methylmalonylcarnitine
Schizophrenia
Key Findings
67 metabolite-disorder associations were identified, involving 44 unique analytes.
21 associations were exclusive to a single disorder: 5 with schizophrenia, 15 with bipolar disorder, and 1 with ADHD.
Inverse association between genetically predicted urinary tyrosine levels and schizophrenia risk was the most robust finding.
Creatine levels were inversely associated with bipolar disorder risk.
22 analytes showed overlap between bipolar disorder and schizophrenia, indicating potential for misdiagnosis.
No significant associations were found for autism spectrum condition, major depressive disorder, or Tourette syndrome.
Schizophrenia-specific analytes clustered into biologically relevant pathways, linking to dopaminergic and glutamatergic signaling.
Clinical Implications
These findings suggest that urinary metabolites may serve as potential biomarkers for psychiatric disorders, particularly in differentiating between schizophrenia and bipolar disorder. However, further validation is necessary before these biomarkers can be integrated into clinical practice, considering the variability of urinary analyte levels due to hydration, diet, and activity levels.
Conclusion
The study highlights the potential of urinary metabolites as biomarkers for psychiatric disorders, emphasizing the need for further research to validate these findings before clinical application, particularly due to the risk of misdiagnosis.
